LRP-5; LRP -6

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Affinity purified

100 ug (0.5 mg/ml) affinity purified rabbit polyclonal antibody in phosphate-buffered saline (PBS) containing 30% glycerol, 0.5% BSA and 0.01% thimerosal.
Appearance: Colorless liquid

0.5 mg/ml (lot specific)

At -20 degree C
Shelf Life: 12 months

Small volumes of anti-LRP-5/6 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Background: LDL-related proteins LRP-5 and LRP-6. are members of the LDL receptor superfamily, which were found to be involved in the canonical Wnt signaling pathway. Mammalian LRP-6 was shown to bind to Wnt-1 and enhance Induced-induced developmental processes in Xenopus embryos. Mice lacking LRP-6 exhibited developmental defects that are similar to those caused by deficiencies in various Want proteins. Recent work also shows that Want proteins induce the binding of LRP-5 to Axin, leading Axin degradation and beta-catenin stabilization.

Western Blot (WB)

Western blotting (0.5-4 ug/ml). However, the optimal concentrations should be determined individually. Jurkat cell lysate can be used as a positive control. The antibody recognizes the ~170 kDa full length LRP-5/6 of human and mouse origins. A cleavage fragment (~120 kDa) can also be detected. Reactivity to other species has not been tested.

179,145 Da

low density lipoprotein receptor-related protein 5

low-density lipoprotein receptor-related protein 5

Low-density lipoprotein receptor-related protein 5

LR3; LRP7; LRP-5??[Similar Products]

LRP5_HUMAN

This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]

LRP5: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor- ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3- mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation. Homodimer; disulfide-linked. Forms phosphorylated oligomer aggregates on Wnt-signaling. Component of a Wnt-signaling complex that contains a WNT protein, a FZD protein and LRP5 or LRP6. Interacts with FZD8; the interaction is formed on WNT-binding and signaling. Interacts (via the phosphorylated PPPSP motif domains) with AXIN1; the interaction prevents inhibition of beta-catenin phosphorylation and signaling and is enhanced in the presence of GSK3B and WNT1 or WNT3A. Interacts (via beta-propeller regions 3 and 4) with DKK1; the interaction, enhanced by MESD and/or KREMEN, inhibits beta-catenin signaling by preventing GSK3-mediated phosphorylation of the PPPSP motifs and subsequent, AXIN1 binding. Interacts with MESD; the interaction prevents the formation of LRP5 aggregates, targets LRP5 to the plasma membrane and, when complexed with KREMEN2, increases DKK1 binding. Interacts with CSNK1E. Interacts with SOST; the interaction antagonizes canonical Wnt signaling. Interacts with APCDD1. Widely expressed, with the highest level of expression in the liver and in aorta. Belongs to the LDLR family.

Protein type: Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 11q13.4

Cellular Component: mitochondrion; endoplasmic reticulum; plasma membrane; integral to membrane; receptor complex

Molecular Function: Wnt-protein binding; Wnt receptor activity; protein binding; toxin transporter activity; coreceptor activity

Biological Process: response to peptide hormone stimulus; somatic stem cell maintenance; positive regulation of transcription, DNA-dependent; Wnt receptor signaling pathway through beta-catenin; bone remodeling; anatomical structure regression; anterior/posterior pattern formation; regulation of apoptosis; regulation of blood pressure; positive regulation of cell proliferation; positive regulation of mesenchymal cell proliferation; negative regulation of osteoblast differentiation; cell migration involved in gastrulation; embryonic limb morphogenesis; cholesterol metabolic process; Wnt receptor signaling pathway; positive regulation of mitosis; regulation of bone remodeling; endocytosis; gastrulation with mouth forming second; osteoblast development; bone marrow development; glucose catabolic process; cholesterol homeostasis; embryonic retina morphogenesis in camera-type eye; positive regulation of osteoblast proliferation; positive regulation of fat cell differentiation; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; embryonic camera-type eye morphogenesis; embryonic digit morphogenesis; retina morphogenesis in camera-type eye

Disease: Osteoporosis-pseudoglioma Syndrome; Van Buchem Disease, Type 2; Osteopetrosis, Autosomal Dominant 1; Exudative Vitreoretinopathy 1; Exudative Vitreoretinopathy 4; Osteoporosis; Bone Mineral Density Quantitative Trait Locus 1; Endosteal Hyperostosis, Autosomal Dominant

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.